─Clinical Trial of PRAME-Targeting Immunotherapy ISA103 in rare ocular cancer to be conducted at MD Anderson Cancer Center─
Oegstgeest, Netherlands and Houston, Texas, January 4, 2023 – ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, today announced that Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA’s PRAME-targeting immunotherapy,
Study designed to investigate the efficacy and safety of ISA101b added to checkpoint inhibitor therapy in Human Papilloma Virus type 16 (HPV16) induced oropharyngeal cancer (OPC).Trial is part of an extensive clinical development program for ISA101b in a collaboration with Regeneron.Top line interim results anticipated in third quarter of 2023.
Oegstgeest, 30 November 2022 – ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, is delighted to announce that it has completed enrolment in its Phase 2 clinical trial named OpcemISA.
The OpcemISA trial has enrolled 194 patients and is a large randomized, double blind,
The Pedro J. Romero Award recognizes individuals who have made outstanding contributions to the cancer immunotherapy fieldSecond SITC award this year to Professor Melief who will be honoured at the 37th SITC Annual Meeting
Oegstgeest, 8 September 2022 – ISA is delighted to announce that our CSO Professor Dr. Cornelis “Kees” Melief has been awarded the 2022 Pedro J. Romero Service to JITC Award by the Society for Immunotherapy of Cancer (SITC). This Award recognizes individuals who made immeasurable contributions to the Journal for Immunotherapy of Cancer (JITC) – the official journal of the SITC. The award will be presented at the SITC’s 37th
Recognition of commendable, longstanding dedication to the field of cancer immunotherapy
Oegstgeest, 15 July 2022 – ISA is delighted to announce that our Chief Scientific Officer (CSO) and Founder, Professor Dr. Cornelis “Kees” Melief has been nominated and selected by the Board of Directors of the Society for Immunotherapy of Cancer (SITC) as a Fellow of the Academy of Immuno-Oncology (FAIO) . The fellowship recognises Prof. Melief’s inspiring contributions and dedication to cancer immunotherapy, and will be presented at the SITC’s 37th Annual Meeting in Boston, 8-12 November 2022.
SITC is a professional society of scientists, clinicians, government representatives, and industry leaders
Oegstgeest, 27 April 2022 – ISA is pleased to announce that its representatives will be participating and presenting at the following business conferences in May 2022. If you would like to meet with our team at any of these events, please contact us through the conference partnering systems or via email@example.com.
LSX World Leaders Congress
Date: 10-11 May 2022, London, UK
Panel Presentation by: Anton Mat, Director Business Development, ISA Pharmaceuticals
Title: Key Multi-Stakeholder Considerations In Early-Stage Commercial Deal-Making
Date & Time: Tuesday, 10 May 2022, 14.30pm BST
Date: 16-18 May 2022, Milan, Italy
Presentation by: Gerben Moolhuizen, Chief Executive Officer, ISA Pharmaceuticals
AMPLIVANT® adjuvant technology has the potential to increase vaccine immune response 10 – 100 foldModi-1 clinical trial to begin in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer
Oegstgeest, The Netherlands, 14 April 2022 – ISA Pharmaceuticals today announces that a clinical trial using ISA’s novel AMPLIVANT® adjuvant technology has started. The trial, run by partner Scancell Holdings plc (AIM: SCLP, “Scancell”) is a multicentre clinical trial, testing the Moditope® vaccine Modi1. This first-in-human clinical trial brings Modi-1 to patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal
Oegstgeest, December 7, 2021 – ISA’s very own Chief Scientific Officer, Cornelis “Kees” Melief, M.D., Ph.D., will be presenting key learnings in cancer vaccine development in an educational session at the ESMO Immune-Oncology Congress 2021, taking place on 8th – 11th December 2021 in Geneva, Switzerland and online.
Key learnings include:
Direct correlation between strength of cancer vaccine-induced immune response and clinical responseCombination therapy of cancer vaccine with standard of care and/or checkpoint blockers necessary for improved outcomes in treatment of late stage cancers
Session: New indications in head and neck (H&N) cancer (incl anaplastic thyroid) (ID 8)Presentation title: HPV vaccination for H&N
Fast Track designation for the treatment of recurrent and metastatic HPV16-positive oropharyngeal cancer to improve survival and delay progression
Oegstgeest, September 14th, 2021 – ISA announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead product ISA101b, for the treatment of recurrent and metastatic oropharyngeal cancer (OPC) that is positive for Human Papilloma Virus type 16 (HPV16).
The Fast Track process is designed to facilitate the development of investigational treatments that demonstrate the potential to address unmet medical needs in serious or life-threatening conditions. Programs with Fast Track designation can benefit from early and frequent
• The phase 2 study enrols patients with advanced HPV16 positive oropharyngeal head and neck cancer that failed previous anti-PD1 treatment• The trial is part of a clinical development plan that is aimed at a Biological License Application (BLA) for this combination immunotherapy
Oegstgeest, The Netherlands, September 8, 2021 – ISA announces the start of patient dosing in a pivotal clinical trial investigating the combination of ISA101b and Libtayo® (cemiplimab) in advanced HPV16 positive oropharyngeal cancer. This new study is the third with active recruitment under ISA Pharmaceuticals’ strategic immuno-oncology collaboration with Regeneron.
The oropharyngeal cancer phase 2 study (NCT04398524) will include
Grant accelerates clinical development of immunotherapy to treat chronic hepatitis B virus infection
Oegstgeest, 20 July 2021 – ISA Pharmaceuticals B.V. is pleased to announce that a consortium between the Erasmus MC and ISA has been awarded a Private-Public Partnerships (PPP) Allowance made available by Health~Holland, Top Sector Life Sciences & Health, to conduct a first-in-human, phase 1 study of ISA104 to treat hepatitis B in chronically infected patients.
The clinical study, to be conducted in close collaboration with the Gastroenterology & Hepatology department of the Erasmus MC, is entitled the ‘HEB-PEP study’. The project starts in August 2021 and the clinical